Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Washington University School of Medicine
Sponsor:
Collaborators:
Columbia University
Northwestern University
Children's Research Institute
University of Utah
Wayne State University
Children's Hospital Medical Center, Cincinnati
University of Michigan
Brown University
University of California, Davis
Information provided by (Responsible Party):
David Schnadower, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01773967
First received: January 10, 2013
Last updated: July 10, 2014
Last verified: July 2014

January 10, 2013
July 10, 2014
July 2014
December 2017   (final data collection date for primary outcome measure)
  • Modified Vesikari Score [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources
  • Severe adverse events [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    presence of severe adverse events up to 1 year after treatment
Same as current
Complete list of historical versions of study NCT01773967 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis

The investigators will study the efficacy and side effect profile of LGG, a probiotic, in pediatric patients with acute gastroenteritis.

Multicenter randomized controlled trial of LGG in patients 3-48 months of age presenting to the Emergency Department with acute gastroenteritis.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Gastroenteritis
  • Drug: LGG
    LGG 10^10 cfu PO BID X 5 days
    Other Names:
    • Lactobacillus GG ATCC 53103
    • Lactobacillus rhamnosus
    • culturelle
  • Drug: micro-crystalline cellulose
    1 capsule PO bid x 5 days
    Other Name: placebo micro-crystalline cellulose
  • Experimental: LGG
    LGG 10^10 cfu PO bid x 5 days
    Intervention: Drug: LGG
  • Placebo Comparator: Placebo
    micro-crystalline cellulose PO bid x 5 days
    Intervention: Drug: micro-crystalline cellulose
Freedman SB, Williamson-Urquhart S, Schuh S, Sherman PM, Farion KJ, Gouin S, Willan AR, Goeree R, Johnson DW, Black K, Schnadower D, Gorelick MH; Pediatric Emergency Research Canada (PERC) Gastroenteritis Study Group. Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial. Trials. 2014 May 14;15:170. doi: 10.1186/1745-6215-15-170.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
900
May 2018
December 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 3-48 months (have not yet reached their fourth birthday); AND
  2. Presence of 3 or more watery stools within 24 hours of screening; AND
  3. Duration of vomiting or diarrhea less than 7 days; AND
  4. Symptoms consistent with acute intestinal infectious process.

Exclusion Criteria:

  1. Presence of an indwelling vascular access line; OR
  2. Presence of structural heart disease excluding non-pathological heart murmurs; OR
  3. Receiving immunosuppressive therapy or history of immunodeficiency; OR
  4. Hematochezia in the preceding 48 hours; OR
  5. Chronic gastrointestinal problems (e.g. short gut syndrome, inflammatory bowel disease); OR
  6. Patients with known pancreatitis; OR
  7. History of abdominal surgery; OR
  8. Critically ill patients; OR
  9. Family member with an indwelling vascular access line, or on immunosuppressive therapy, or with a known immunodeficiency; OR
  10. Bilious emesis; OR
  11. Probiotic use (supplement) in the preceding 2 weeks; OR
  12. Oral or intravenous steroid use in the preceding six months; OR
  13. Previously enrolled in this trial; OR
  14. Allergy to lactobacillus or Microcrystalline Cellulose (MCC); OR
  15. Allergy to erythromycin, clindamycin, AND betalactam antibiotics (all); OR
  16. Not available for daily follow-up while symptomatic; OR
  17. Parent/guardian not speaking English or Spanish; OR
  18. Under 6 months old AND premature (<37 weeks).
Both
3 Months to 48 Months
No
Contact: David Schnadower, MD 314 747 5604 schnadower_d@kids.wustl.edu
Contact: Phillip I Tarr, MD 314 286 2848 Tarr@kids.wustl.edu
United States
 
NCT01773967
1 R01 HD071915-02
Yes
David Schnadower, Washington University School of Medicine
Washington University School of Medicine
  • Columbia University
  • Northwestern University
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Children's Research Institute
  • University of Utah
  • Wayne State University
  • Children's Hospital Medical Center, Cincinnati
  • University of Michigan
  • Brown University
  • University of California, Davis
Principal Investigator: David Schnadower, MD Washington University School of Medicine
Washington University School of Medicine
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP